Skinner R, Pearson A D, Amineddine H A, Mathias D B, Craft A W
Department of Child Health, University of Newcastle upon Tyne, Medical School, UK.
Br J Cancer. 1990 Jun;61(6):927-31. doi: 10.1038/bjc.1990.208.
Twenty-two children and adolescents who had received cisplatinum for the treatment of solid tumours underwent audiometry to ascertain the extent of hearing damage. Five patients complained of hearing difficulties, causing difficulty at school in one child. Hearing loss greater than 20 decibels occurred in four patients at 1,000 Hz, seven at 2,000 Hz, 13 at 4,000 Hz and 21 at 8,000 Hz. Median hearing loss was greater at higher frequencies (P less than 0.0001), and with increasing cumulative dose of cisplatinum. However, a 'plateau' phenomenon was observed, with no apparent further deterioration in hearing loss at doses greater than 600 mg m-2. Two children who had received prior aural radiotherapy had severe hearing loss. Severe, mostly asymptomatic, ototoxicity is common in children given cisplatinum. However, there is considerable interpatient variability in the hearing loss suffered.
22名接受顺铂治疗实体瘤的儿童和青少年接受了听力测定，以确定听力损害的程度。5名患者抱怨听力困难，其中1名儿童在学校因此遇到困难。在1000Hz时，4名患者出现大于20分贝的听力损失；在2000Hz时，7名患者出现；在4000Hz时，13名患者出现；在8000Hz时，21名患者出现。高频时听力损失中位数更大（P小于0.0001），且随着顺铂累积剂量增加而增大。然而，观察到一种“平台”现象，即剂量大于600mg/m²时听力损失无明显进一步恶化。2名先前接受过耳部放疗的儿童有严重听力损失。给予顺铂的儿童中严重的、大多无症状的耳毒性很常见。然而，患者间听力损失存在相当大的差异。
